|Previous Section||Index||Home Page|
Anne Milton: To ask the Secretary of State for Health what drugs for the treatment of cancer the National Institute for Health and Clinical Excellence has (a) recommended and (b) not recommended for NHS use since 1 November 2008; how long the appraisal of each took; and whether the pharmaceutical company supplying each such drug offered to make it available on a risk-sharing basis. 
Mr. Mike O'Brien: The information requested is shown in the table. For each of the appraisals, the table shows whether one or more Patient Access Schemes agreed between the Department of Health and the manufacturer have been considered by the National Institute for Health and Clinical Excellence (NICE).
|Topic||Start of NICE appraisal( 1)||Date of final NICE guidance||Recommendation||Patient access scheme considered by NICE|
Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
|(1) The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.|
(2) This is the date on which the Multiple Technology Appraisal (MTA) began for Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (first and second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. The MTA was subsequently split and Sutent (sunitinib) for the first-line treatment of renal cell carcinoma was considered in a separate single technology appraisal.
Mr. Willis: To ask the Secretary of State for Health pursuant to the answer of 4 March 2010, Official Report, columns 1397-8W, on complementary medicine, which complementary or alternative treatments, medicines or therapies the National Institute for Health and Clinical Excellence has (a) considered and (b) approved for use by NHS clinicians. 
|A summary of National Institute for Health and Clinical Excellence recommendations relating to complementary and alternative medicines|
|Guidance topic||Publication date||Recommendation|
The Alexander Technique may be offered to benefit people with Parkinson's disease (PD) by helping them to make lifestyle adjustments that affect both the physical nature of the condition and the person's attitude to having PD.
When organising supportive and palliative care services for people with cancer, commissioners and the NHS and voluntary sector providers should work in partnership across a Cancer Network to decide how to best meet the needs of patients for complementary therapies where there is evidence to support their use. As a minimum, high quality information should be made available to patients about complementary therapies and services. Provider organisations should ensure that any practitioner delivering complementary therapies in NHS settings conforms to policies designed to ensure best practice agreed by the Cancer Network.
Informing people with hypertension that relaxation therapies can reduce blood pressure and individual patients may wish to pursue these as part of their treatment. However, routine provision by primary care teams is not currently recommended. Examples include: stress management, meditation, cognitive therapies, muscle relaxation and biofeedback.
Although there is evidence that St. John's wort may be of benefit in mild or moderate depression, health care professionals should not prescribe or advise its use by patients because of uncertainty about appropriate doses, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants).
Consider offering a course of manual therapy, including spinal manipulation, spinal mobilisation and massage. Treatment may be provided by a range of health professionals including chiropractors, osteopaths, manipulative physiotherapists or doctors who have had specialist training Consider offering a course of acupuncture needling, up to a maximum of 10 sessions over a period of up to 12 weeks Injections of therapeutic substances into the back for non-specific low back pain are not recommended.
Bob Spink: To ask the Secretary of State for Health how many and what proportion of patients treated by the NHS for drug addiction and resident in (a) Essex and (b) Castle Point constituency were no longer addicted at the end of their treatment in each of the last five years. 
Gillian Merron: Information is not available in the format requested. National Drug Treatment Monitoring System (NDTMS) data are not collected at the Castle Point constituency level. The NDTMS data available for adults in Essex completing drug treatment free from dependency are as follows:
| Note: Data prior to 2005-06 are not robust enough to be reported at local drug action team level.|
Sir Gerald Kaufman: To ask the Secretary of State for Health if he will set out, with statistical information related as directly as possible to Manchester, Gorton constituency, the effects on that constituency of his Department's policies since 1997. 
Ann Keen: The Government have put in place a programme of national health service investment and reform since 1997 to improve service delivery in all parts of the United Kingdom. 93 per cent. of people nationally now rate the NHS as good or excellent. The NHS constitution contains 25 rights and 14 pledges for patients and the public including new rights to be treated within 18 weeks, or be seen by a cancer specialist within two weeks and an NHS health check every five years for those aged 40-74 years.
Figures for December 2009 show that in the Manchester Primary Care Trust (PCT):
87 per cent. of patients whose treatment involved admission to hospital started their treatment within 18 weeks.
97 per cent. of patients whose treatment did not involve admission to hospital started their treatment within 18 weeks.
In December 2009, at the Central Manchester University Hospitals NHS Foundation Trust, 98.0 per cent. of patients spent less than four hours in accident and emergency from arrival to admission, transfer or discharge.
Between September 2002 and September 2008, the number of consultants at the Central Manchester University Hospitals NHS Foundation Trust has increased from 304 to 366. Between September 2002 and September 2008 the estimated number of nurses has increased from 2,383 to 3,274.
Between September 2001 and September 2008 the number of general practitioners (GP) per 100,000 within the Manchester PCT area has increased from 67.9 to 70.3.
85.6 per cent. of urgent GP referrals to the Central Manchester University Hospitals NHS Foundation Trust with suspected cancer are seen by a specialist within two weeks of the referral (as at December 2009).
A £512 million private finance initiative (PFI) scheme to replace many of Central Manchester University Hospital NHS Foundation Trust's existing hospitals into a linked development on the Manchester Royal Infirmary (Oxford Road) site is now complete. It includes:
The new Manchester Royal Eye Hospital, which opened to patients in August 2009;
The new Manchester Royal Infirmary wing, which opened to patients in August 2009;
The new Royal Manchester Children's Hospital opened to patients in June 2009. It brings together the specialist services previously provided at the Booth Hall and Pendlebury Children's
Hospitals. The new children's hospital includes the paediatric intensive care unit which is one of the leading centres in the North West and a paediatric emergency department.
Since 1997, gross current expenditure on personal social services has increased by around 70 per cent. in real terms with around 105,000 households now receiving intensive home care and 3,076 new extra care housing units-exceeding the original target of 1,500 new extra care units.
|Next Section||Index||Home Page|